Navigation Links
MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
Date:11/3/2008

GAITHERSBURG, Md., Nov. 3 /PRNewswire/ -- MedImmune today announced that it has initiated a Phase 1/2a clinical trial of a live, attenuated intranasal vaccine in healthy children one month to 12 months of age to help prevent severe respiratory syncytial virus (RSV) infections. RSV is the most common respiratory infection in infants and can cause disease in otherwise healthy infants and children.

"RSV is a serious respiratory disease that can have significant effects on children. As a leader in pediatric medicine, MedImmune is committed to developing therapies that can combat the most common cause of pediatric respiratory illness," said Filip Dubovsky, M.D., M.P.H, vice president, clinical development, vaccines. "Because respiratory illness due to RSV occurs in otherwise healthy children, developing a vaccine is a public health priority."

MedImmune is a world leader in the development of innovative therapeutic biologic products for prophylaxis and prevention of infectious diseases. This Phase 1/2a clinical trial is designed to assess the safety, tolerability, immunogenicity and viral shedding of the intranasal RSV vaccine in infants and young children. It is a randomized, double-blind, placebo-controlled and multi-dose study that will enroll 320 children.

The investigational vaccine, MEDI-559, is being developed through a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NAID), part of the National Institutes of Health, to help address RSV disease in children. The vaccine was originally developed in the NAID Division of Intramural Research by a team led by Peter L. Collins, Ph.D. and Brian R. Murphy, M.D.

About RSV

RSV is the most important cause of viral lower respiratory tract illness in infants worldwide. Each year, an estimated 125,000 infants in the United States are hospitalized with severe RSV infections. RSV is the most common respiratory infection in infancy or childhood that circulates in the Northern Hemisphere predominantly in the fall and winter months. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday.

About MedImmune

MedImmune is a leading innovation-focused biotechnology company whose mission it is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular / gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
4. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
5. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
6. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
7. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
8. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
9. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
10. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
11. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... The key factors driving the growth of dialysis ... growth and increasing healthcare expenditure. Some of the noteworthy trends ... ESRD patients, rising demand for home PD treatment and huge ... market is hindered by high treatment costs and stringent regulations. ... Complete ...
(Date:3/23/2017)... -- Transportation Insight, a multi-modal lead logistics solutions provider receives ... with expertise serving clients in the food industry. Vice ... was named a 2017 Food Logistics Champion: ... publication exclusively dedicated to covering the movement of product ... has brought to Transportation Insight a wealth of knowledge ...
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017 /PRNewswire/ ... and the William Sansum Diabetes Center have established a ... affected by diabetes through enhanced research, education and care. ... cardiovascular disease bears a disproportionate weight on Latino families ... David Kerr , M.D., FRCPE, director of Innovation ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of Saints: ... of God in congregations across the United States. “The Communion of Saints” ... 1964 who has served congregations in seven states throughout his long career of ...
(Date:3/23/2017)... ... 2017 , ... The physicians of KSF Orthopaedic Center PA are proud to ... location is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 ... provide patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The IoT ... and WiFi connectivity are making a huge impact on businesses and individual consumers alike. ... estimates the IoT will have a value anywhere from $4 trillion to $11 trillion ...
(Date:3/23/2017)... ... March 23, 2017 , ... March is National Kidney Month – the ... it comes to maintaining good health. Every day, two kidneys filter about 120 to ... drop of your blood, eliminating waste, regulating fluid levels and blood pressure, supporting bone ...
(Date:3/23/2017)... ... 23, 2017 , ... The Wound Certification Prep Course ... Holdings, LLC, today announced that RestorixHealth® has officially endorsed WCPC as ... interested in becoming Certified Wound Specialist Physicians (CWSP®). , This collaborative effort ...
Breaking Medicine News(10 mins):